Trial Profile

Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 Results of analysis assessing potential baseline factors that may influence urate-lowering response to pegloticas using data from Phase 3 pegloticase registration and MIRROR RCT2 trials presented at the ACR Convergence 2023
06 Jan 2021 Results of post-hoc analysis of two studies (NCT00325195 & NCT01356498) assessing factors associated with gout flares in subjects treated with pegloticase, published in the Clinical and Experimental Rheumatology.
21 Mar 2019 According to an AMPEL BioSolutions media release, results evaluating the characteristics and response to pegloticase of patients with chronic refractory gout with and without clinically apparent tophi, from two clinical trials, (NCT00325195, NCT01356498) were published in Rheumatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com